Low-grade glioneuronal tumour with novel molecular features associated with unusual partial epilepsy in a child

Yan Yuen Lo,¹ Denise M Malicki,² Michael L Levy,³ John Ross Crawford⁴

¹Neurosciences, University of California San Diego, La Jolla, California, USA

²Pathology, Rady Children's Hospital University of California San Diego, San Diego, California, USA

³Neurosurgery, University of California San Diego, San Diego, California, USA

⁴Neurosciences and Pediatrics, University of California San Diego, San Diego, California, USA

Correspondence to

Dr John Ross Crawford;
jrcrawford@ucsd.edu

Accepted 7 August 2020

DESCRIPTION

A 10-year previously healthy boy presented with unusual episodes of recurrent frontal headaches lasting 30 s associated with the abnormal smell that would occur several times per week. He had no focal weakness, sensory changes or loss of consciousness during the episodes and had a non-focal neurological examination. He was seen in the emergency room for intractable headache where MRI for brain was performed that revealed a T2-hyperintense left mesial temporal lobe mass without enhancement (figure 1). He was subsequently admitted and underwent a robotic-guided stereotactic biopsy that demonstrated a moderately cellular proliferation of round cells with round nuclei, perinuclear halos and a myxoid background, with a small number of scattered admixed mature neurons. Neuronal cells seen appeared irregularly scattered and surrounded by myxoid material, without satellitosis by smaller cells, and were interpreted as a component of the lesion. A small number of scattered mitotic figures were seen without vascular proliferation or necrosis and the Ki-67 labelling index ranged from 1% to 5%. Overall the constellation of histopathological findings was most consistent with a diagnosis of low-grade glioneuronal tumour with features of dysembryoplastic neuroepithelial tumour (figure 2). DNA-based next-generation sequencing panel consisting of 397 cancer-related genes as previously described,¹ performed on paraffin-embedded formalin-fixed tumour revealed no reportable mutations and variant of unknown significance of *KAT6A*. However, chromosomal microarray analysis revealed hyperdiploidy with 77 kb loss at 7q34 encompassing *BRAF* exons 2–9. In addition there were single copy gains (chromosomes 2,3,10,12,14,16,17,19,20) and high copy gains (chromosomes 6–9, 3q13.2-q13.31).

Figure 1 Axial fluid-attenuated inversion recovery MRI sequences (A) demonstrated a hyperintense mass involving the left amygdala and hippocampus without enhancement on postgadolinium sequences (B).

Figure 2 (A) H&E staining of the tumour revealed a moderately cellular proliferation of round cells with round nuclei, perinuclear halos and a myxoid background, with a small number of scattered admixed mature neurons. Neuronal cells seen appeared irregularly scattered and surrounded by myxoid material, without satellitosis by smaller cells, and were interpreted as a component of the lesion. A small number of scattered mitotic figures were seen without vascular proliferation or necrosis. (B) The Ki-67 labelling index ranged from 1% to 5%. Overall the constellation of findings is consistent with a diagnosis of low-grade glioneuronal tumour with overlapping features of dysembryoplastic neuroepithelial tumour.

Following surgery, the patient had continued auras that prompted unsuccessful treatment with two anticonvulsant therapies. A prolonged video electroencephalogram (EEG) captured several olfactory auras associated with headache; however, there was no electrographic seizure correlate seen on surface electrodes. The patient is undergoing workup for intractable epilepsy that includes stereotactic EEG recordings given the deep-seated tumour location. Follow-up neuroimaging 1 year after diagnosis reveals no evidence of tumour recurrence or progression.

Paediatric low-grade gliomas are the most common brain tumours of childhood and are driven by genetic alterations in the RAS/mitogen-activated protein kinase pathway.^{2–4} Two-thirds of

© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Lo YY, Malicki DM, Levy ML, et al. *BMJ Case Rep* 2020;**13**:e237373. doi:10.1136/bcr-2020-237373

Images in...

paediatric low-grade gliomas contain alterations in *NF1*, *BRAF-KIAA1549* fusions and *BRAFV600E* mutations.³ However, mutations in *FGFR*, *MYB* and other single nucleotide variants and rearrangements have been identified.²⁻⁴ Paediatric low-grade gliomas with gene rearrangements have improved progression-free survivals than those with single nucleotide variants.³ The targeted mutations have led changes in management using biologics in the treatment of paediatric low-grade glioma.⁵ The deletion involving exons 2–9 of *BRAF*, which includes the Ras-binding domain, has been described as a possible mechanism of resistance to B-Raf Proto-Oncogene, Serine/Threonine Kinase (*BRAF*) and Mitogen-activated protein kinase kinase (*MEK*) inhibition in other non-central nervous system tumours.⁶ It is unclear what the clinical ramifications of the *BRAF* exon 2–9 deletion identified would be in the case of a low-grade glioneuronal tumour in the absence of RNA sequencing data. Our case

highlights the limitations of detecting some *BRAF* alterations by next generation sequencing, especially in cases of large deletions and the potential utility of microarray in the appropriate clinical setting. In summary, the novel histological and molecular features expand the current knowledge and highlight the genetic and clinical diversity of paediatric low-grade glioma.

Contributors YYL contributed to the design and writing of the manuscript. DMM contributed to the design and writing of the manuscript. MLL contributed to the design and writing of the manuscript. JRC contributed to the design and writing of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Parental/guardian consent obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Learning points

- ▶ Paediatric glioneuronal tumours are occasionally difficult to classify by WHO criteria and rarely show aggressive clinical behaviour.
- ▶ Paediatric low-grade glioma is RAS/mitogen-activated protein kinase driven tumours in the majority of cases and are commonly associated with *NF1* mutations, *BRAF-KIAA1549* fusion and *V600E* mutations.
- ▶ Next-generation sequencing may not detect all *BRAF* variants, especially those involving large deletions and microarray testing may be warranted in the appropriate clinical setting.

REFERENCES

- 1 Burgoyne AM, De Siena M, Alkhuziem M, *et al.* Duodenal-jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic *NF1* and Notch Pathway Mutations. *JCO Precis Oncol* 2017;2017. doi:10.1200/PO.17.00014. [Epub ahead of print: 15 Aug 2017].
- 2 Johnson A, Severson E, Gay L, *et al.* Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. *Oncologist* 2017;22:1478–90.
- 3 Ryall S, Zapotocky M, Fukuoka K, *et al.* Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. *Cancer Cell* 2020;37:569–83.
- 4 Qaddoumi I, Orisme W, Wen J, *et al.* Genetic alterations in uncommon low-grade neuroepithelial tumors: *BRAF*, *FGFR1*, and *Myb* mutations occur at high frequency and align with morphology. *Acta Neuropathol* 2016;131:833–45.
- 5 Jones DTW, Kieran MW, Bouffet E, *et al.* Pediatric low-grade gliomas: next biologically driven steps. *Neuro Oncol* 2018;20:160–73.
- 6 Johnson DB, Childress MA, Chalmers ZR, *et al.* *Braf* internal deletions and resistance to *BRAF/MEK* inhibitor therapy. *Pigment Cell Melanoma Res* 2018;31:432–6.

Copyright 2020 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <https://www.bmj.com/company/products-services/rights-and-licensing/permissions/>
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow